Jessan A. Jishu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jessan A. Jishu has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
- Eman Ali Toraih
Department of Cardiovascular Perfusion, College of Health Professions, Upstate Medical University, New York, NY 13210, USA
12 shared publications - Manal Said Fawzy
Center for Health Research, Northern Border University
9 shared publications - Mohammad Hosny Hussein
Ochsner Clinic Foundation, New Orleans, LA 70112, USA
7 shared publications - Emad Kandil
Department of Surgery Tulane University School of Medicine New Orleans Louisiana USA
6 shared publications Alexandra LaForteza
Louisiana State University Health Sciences Center School of Medicine
3 shared publicationsAhmed Abdelmaksoud
Department of Internal Medicine University of California Riverside California USA
2 shared publications
Latest Publications
- 24 July 2026
- Published by SAGE Publications in The American Surgeon™
Permanent Hypoparathyroidism After Total Thyroidectomy Is Associated With Chronic Kidney Disease
Background: Permanent hypoparathyroidism (PHypoPT) is common after total thyroidectomy (TT), yet the persistence and magnitude of renal consequences following this complication have not been characterized in large-scale populations. Methods: Between January 2004 and December 2024, adult patients who underwent TT were identified from the TriNetX Research Network. Propensity matching was performed on age, demographics, and comorbidities. The primary outcomes were the incidence of CKD and burden of renal impairment; the secondary outcome was mortality. All outcomes were followed over 10 years. Results: We identified 73,999 patients who underwent TT, of whom 2706 developed subsequent PHypoPT. After matching, there were 2691 patients per cohort. PHypoPT was associated with a significantly increased risk of developing CKD (HR 1.67, 95% CI: 1.39-2.02) with decreased mean estimated glomerular filtration rate (78.5 ± 26.3 mL/min/1.73 m 2 vs 83.1 ± 25.5 mL/min/1.73 m 2 , P < .01). The risk for CKD was increased in both early (HR 2.18, 95% CI: 1.75-2.71) and late (HR 2.75, 95% CI: 1.62-4.69) stages. When stratifying by indication, the increased risk persisted in patients with thyroid cancer (HR 1.70, 95% CI: 1.26-2.30), thyrotoxicosis (HR 2.41, 95% CI: 1.55-3.73), and goiter (HR 2.00, 95% CI: 1.58-2.45). There were no differences in risks for mortality. Conclusions: PHypoPT after TT for both benign and malignant disease demonstrates an increased risk of CKD with worsening burden over time, indicating that this surgical complication may have systemic consequences that extend beyond postoperative care. Prospective studies should confirm such findings and assess the need for heightened surveillance in affected patients.
- 24 July 2026
- Published by SAGE Publications in The American Surgeon™
Permanent Hypoparathyroidism After Total Thyroidectomy Is Associated With Chronic Kidney Disease
Background: Permanent hypoparathyroidism (PHypoPT) is common after total thyroidectomy (TT), yet the persistence and magnitude of renal consequences following this complication have not been characterized in large-scale populations. Methods: Between January 2004 and December 2024, adult patients who underwent TT were identified from the TriNetX Research Network. Propensity matching was performed on age, demographics, and comorbidities. The primary outcomes were the incidence of CKD and burden of renal impairment; the secondary outcome was mortality. All outcomes were followed over 10 years. Results: We identified 73,999 patients who underwent TT, of whom 2706 developed subsequent PHypoPT. After matching, there were 2691 patients per cohort. PHypoPT was associated with a significantly increased risk of developing CKD (HR 1.67, 95% CI: 1.39-2.02) with decreased mean estimated glomerular filtration rate (78.5 ± 26.3 mL/min/1.73 m 2 vs 83.1 ± 25.5 mL/min/1.73 m 2 , P < .01). The risk for CKD was increased in both early (HR 2.18, 95% CI: 1.75-2.71) and late (HR 2.75, 95% CI: 1.62-4.69) stages. When stratifying by indication, the increased risk persisted in patients with thyroid cancer (HR 1.70, 95% CI: 1.26-2.30), thyrotoxicosis (HR 2.41, 95% CI: 1.55-3.73), and goiter (HR 2.00, 95% CI: 1.58-2.45). There were no differences in risks for mortality. Conclusions: PHypoPT after TT for both benign and malignant disease demonstrates an increased risk of CKD with worsening burden over time, indicating that this surgical complication may have systemic consequences that extend beyond postoperative care. Prospective studies should confirm such findings and assess the need for heightened surveillance in affected patients.
- Open Access
- 12 June 2026
- Published by Wiley in The Laryngoscope
- Vol. 136 (10) , 4589-4595
Rare But Risky: Clinical Impacts of Pneumothorax After Thyroidectomy and Parathyroidectomy
Objective: Postoperative pneumothorax (PPTX) after thyroidectomy (TD) or parathyroidectomy (PT) is rare and primarily described in case reports with limited data on its prognostic significance in large populations. We aim to assess the incidence of PPTX and its association with clinical outcomes following TD or PT. Methods: We queried the TriNetX United States Research Network, identifying patients ≥ 18 years of age who underwent open TD or PT between January 2000 and December 2025. Patients were separated by development of PTX within 7 days postoperatively. Outcomes were assessed at 3 and 6 months using odds ratios (ORs) and at 1 year using hazard ratios (HRs), with 95% confidence intervals (CIs). The primary outcome was all‐cause mortality; secondary outcomes included risks for pneumonia, dysphagia, vocal cord paralysis, and need for mechanical ventilation as well as healthcare utilization rates. Results: Among 228,340 patients undergoing surgery, 237 (0.10%) developed PPTX. At 1 year, PPTX was associated with increased risk of all‐cause mortality (HR 16.44, 95% CI 11.16–24.23), pneumonia (HR 6.14, 95% CI 3.48–10.83), dysphagia (HR 4.86, 95% CI 3.23–7.33), vocal cord paralysis (HR 5.19, 95% CI 3.31–8.15), and need for mechanical ventilation (HR 18.13, 95% CI 10.89–30.17). PPTX was also associated with higher rates of hospital readmission (HR 15.12, 95% CI 11.97–19.10) and emergency room visits (HR 2.09, 95% CI 1.33–2.28) (all p < 0.01). All outcomes were also significant at 3 and 6 months after surgery. Conclusion: PPTX after TD or PT is exceedingly uncommon but associated with significantly worse mortality and morbidity. Level of Evidence: 3
- 12 June 2026
- Published by Wiley in The Laryngoscope
- Vol. 136 (10) , 4589-4595
Open AccessRare But Risky: Clinical Impacts of Pneumothorax After Thyroidectomy and Parathyroidectomy
Objective: Postoperative pneumothorax (PPTX) after thyroidectomy (TD) or parathyroidectomy (PT) is rare and primarily described in case reports with limited data on its prognostic significance in large populations. We aim to assess the incidence of PPTX and its association with clinical outcomes following TD or PT. Methods: We queried the TriNetX United States Research Network, identifying patients ≥ 18 years of age who underwent open TD or PT between January 2000 and December 2025. Patients were separated by development of PTX within 7 days postoperatively. Outcomes were assessed at 3 and 6 months using odds ratios (ORs) and at 1 year using hazard ratios (HRs), with 95% confidence intervals (CIs). The primary outcome was all‐cause mortality; secondary outcomes included risks for pneumonia, dysphagia, vocal cord paralysis, and need for mechanical ventilation as well as healthcare utilization rates. Results: Among 228,340 patients undergoing surgery, 237 (0.10%) developed PPTX. At 1 year, PPTX was associated with increased risk of all‐cause mortality (HR 16.44, 95% CI 11.16–24.23), pneumonia (HR 6.14, 95% CI 3.48–10.83), dysphagia (HR 4.86, 95% CI 3.23–7.33), vocal cord paralysis (HR 5.19, 95% CI 3.31–8.15), and need for mechanical ventilation (HR 18.13, 95% CI 10.89–30.17). PPTX was also associated with higher rates of hospital readmission (HR 15.12, 95% CI 11.97–19.10) and emergency room visits (HR 2.09, 95% CI 1.33–2.28) (all p < 0.01). All outcomes were also significant at 3 and 6 months after surgery. Conclusion: PPTX after TD or PT is exceedingly uncommon but associated with significantly worse mortality and morbidity. Level of Evidence: 3
- Open Access
- 18 May 2026
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 9 (3) , e70239
Clinical Outcomes of Selenium Supplementation in Hashimoto's Thyroiditis Without Selenium Deficiency: A Large‐Scale Retrospective Cohort Study
Introduction: Selenium supplementation has been suggested as a therapeutic option for Hashimoto's thyroiditis, but its effects on thyroid function and other patient‐related outcomes remain unclear. Methods: This retrospective cohort study utilised a global federated health research network to compare patients with Hashimoto's thyroiditis who received selenium supplementation after diagnosis to those who did not. Propensity score matching was performed to balance baseline characteristics. Primary outcomes included longitudinal thyroid function measures, while secondary outcomes included development of autoimmune diseases, thyroid cancer, need for thyroidectomy and all‐cause mortality. All outcomes were followed for 5 years. Results: After matching, 2347 patients were included in each cohort. Selenium supplementation was associated with persistently higher mean TSH, free T4 and TPOAb levels, as well as greater proportions of elevated TPOAb (> 35 IU/mL) at 3 years (6.9% vs. 5.0%, p = 0.01) and 5 years (7.9% vs. 5.3%, p < 0.01). The incidence of autoimmune disorders was higher in the selenium group (RR 1.33, 95% CI 1.14–1.56), particularly Sjögren's syndrome (RR 1.61, 95% CI 1.03–2.52) and psoriasis (RR 2.69, 95% CI 1.52–4.76). The rates of thyroid cancer and need for thyroidectomy were similar between groups. However, selenium use was associated with increased all‐cause mortality (RR 1.38, 95% CI 1.09–2.03). Conclusion: Selenium supplementation in Hashimoto's thyroiditis was associated with worsened biochemical autoimmunity, increased autoimmune comorbidity and higher mortality. These findings should be interpreted cautiously given the absence of baseline selenium measurements, which limits assessment of deficiency status. Nevertheless, they highlight the need for further research to confirm these results.
- 18 May 2026
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 9 (3) , e70239
Open AccessClinical Outcomes of Selenium Supplementation in Hashimoto's Thyroiditis Without Selenium Deficiency: A Large‐Scale Retrospective Cohort Study
Introduction: Selenium supplementation has been suggested as a therapeutic option for Hashimoto's thyroiditis, but its effects on thyroid function and other patient‐related outcomes remain unclear. Methods: This retrospective cohort study utilised a global federated health research network to compare patients with Hashimoto's thyroiditis who received selenium supplementation after diagnosis to those who did not. Propensity score matching was performed to balance baseline characteristics. Primary outcomes included longitudinal thyroid function measures, while secondary outcomes included development of autoimmune diseases, thyroid cancer, need for thyroidectomy and all‐cause mortality. All outcomes were followed for 5 years. Results: After matching, 2347 patients were included in each cohort. Selenium supplementation was associated with persistently higher mean TSH, free T4 and TPOAb levels, as well as greater proportions of elevated TPOAb (> 35 IU/mL) at 3 years (6.9% vs. 5.0%, p = 0.01) and 5 years (7.9% vs. 5.3%, p < 0.01). The incidence of autoimmune disorders was higher in the selenium group (RR 1.33, 95% CI 1.14–1.56), particularly Sjögren's syndrome (RR 1.61, 95% CI 1.03–2.52) and psoriasis (RR 2.69, 95% CI 1.52–4.76). The rates of thyroid cancer and need for thyroidectomy were similar between groups. However, selenium use was associated with increased all‐cause mortality (RR 1.38, 95% CI 1.09–2.03). Conclusion: Selenium supplementation in Hashimoto's thyroiditis was associated with worsened biochemical autoimmunity, increased autoimmune comorbidity and higher mortality. These findings should be interpreted cautiously given the absence of baseline selenium measurements, which limits assessment of deficiency status. Nevertheless, they highlight the need for further research to confirm these results.
- Open Access
- 4 May 2026
- Published by Elsevier in JTCVS Open
- Vol. 32
Mortality and morbidity benefits of surgical versus transcatheter aortic valve replacement in patients ≤60 years: Findings from a national cohort
- 4 May 2026
- Published by Elsevier in JTCVS Open
- Vol. 32
Open AccessMortality and morbidity benefits of surgical versus transcatheter aortic valve replacement in patients ≤60 years: Findings from a national cohort
- Open Access
- 5 February 2026
- Published by Springer Nature in International Ophthalmology
- Vol. 46 (1) , 103
Complications of minimally invasive surgery for primary open-angle glaucoma in patients with diabetic retinopathy: a retrospective cohort study
Objective: Minimally invasive glaucoma surgery (MIGS) has become increasingly popular for treating primary open-angle glaucoma (POAG). However, data regarding complications for patients with comorbid diabetic retinopathy (DR) are limited. This study aimed to compare complications after MIGS in POAG patients with and without DR. Methods: This is a retrospective cohort study using the TriNetX global health network. Adult patients with POAG who underwent MIGS were identified, with one group having comorbid DR and the other without. Propensity score matching was applied, yielding 518 patients per group for analysis. Complications assessed included vision loss, hypotony, ocular hypertension, cataract formation, eye infection, and any ocular hemorrhage. The primary outcomes were post-procedure complication rates and their statistical significance. Hazard ratios (HRs) with 95% confidence intervals (CIs) were computed. Results: Patients with DR who underwent MIGS had a higher risk for vision loss (32.8% vs. 24.4%, HR 1.443, 95% CI 1.13–1.841) and ocular hemorrhage (13.4% vs. 4.3%, HR 3.194, 95% CI 1.929–5.288) compared to those without DR. Cataract formation rates were lower in DR patients at 3 months (44.4% vs. 50.6%, p = 0.046) and 6 months (53.3% vs. 59.5%, p = 0.048) post-surgery. No significant differences were observed in rates of hypotony, ocular hypertension, or eye infection. Conclusion: MIGS in patients with DR is associated with an increased risk of post-procedure complications, particularly vision loss and ocular hemorrhage. These findings can aid in the clinical management and counseling of patients with both POAG and DR considering MIGS.
- 5 February 2026
- Published by Springer Nature in International Ophthalmology
- Vol. 46 (1) , 103
Open AccessComplications of minimally invasive surgery for primary open-angle glaucoma in patients with diabetic retinopathy: a retrospective cohort study
Objective: Minimally invasive glaucoma surgery (MIGS) has become increasingly popular for treating primary open-angle glaucoma (POAG). However, data regarding complications for patients with comorbid diabetic retinopathy (DR) are limited. This study aimed to compare complications after MIGS in POAG patients with and without DR. Methods: This is a retrospective cohort study using the TriNetX global health network. Adult patients with POAG who underwent MIGS were identified, with one group having comorbid DR and the other without. Propensity score matching was applied, yielding 518 patients per group for analysis. Complications assessed included vision loss, hypotony, ocular hypertension, cataract formation, eye infection, and any ocular hemorrhage. The primary outcomes were post-procedure complication rates and their statistical significance. Hazard ratios (HRs) with 95% confidence intervals (CIs) were computed. Results: Patients with DR who underwent MIGS had a higher risk for vision loss (32.8% vs. 24.4%, HR 1.443, 95% CI 1.13–1.841) and ocular hemorrhage (13.4% vs. 4.3%, HR 3.194, 95% CI 1.929–5.288) compared to those without DR. Cataract formation rates were lower in DR patients at 3 months (44.4% vs. 50.6%, p = 0.046) and 6 months (53.3% vs. 59.5%, p = 0.048) post-surgery. No significant differences were observed in rates of hypotony, ocular hypertension, or eye infection. Conclusion: MIGS in patients with DR is associated with an increased risk of post-procedure complications, particularly vision loss and ocular hemorrhage. These findings can aid in the clinical management and counseling of patients with both POAG and DR considering MIGS.
- Open Access
- 1 January 2026
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 2026 (1)
Experiences and Outcomes of Primary Care Delivery Between Physicians and Nurse Practitioners: A Narrative Review
There is a growing demand for primary care physicians (PCPs) in the United States due to an increasing physician shortage and a growing burden of chronic disease. As such, nurse practitioners (NPs) have increasingly served as frontline clinicians alongside PCPs. This narrative review aims to describe the scopes, responsibilities, and outcomes of primary care practice between the two professions. A comprehensive review of the literature was performed to explore similarities and differences in the practice, quality of care, patient satisfaction, access to services, and professional challenges faced by both provider groups. Evidence suggests that PCPs and NPs provide complementary care to improve healthcare access. PCPs and NPs share similar responsibilities, including but not limited to examining patients, diagnosing diseases, managing acute and chronic illnesses, developing treatment plans, and coordinating care. PCPs undergo more extensive training, manage complex and invasive procedures, and maintain higher confidence in performing such tasks. Clinical outcomes under NP care are generally comparable to physician care across common or mild primary care conditions. PCPs often have more successful outcomes with severe or complex diseases, managing severe psychiatric conditions, and delivering advanced procedures or therapies. However, higher patient satisfaction is reported with management by NPs. Evidence on prescribing patterns, particularly opioids, is mixed across regulatory environments. This review highlights the need for integrated care models and policy frameworks that optimize collaboration between physicians and NPs, ultimately strengthening the primary care workforce and improving population health outcomes.
- 1 January 2026
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 2026 (1)
Open AccessExperiences and Outcomes of Primary Care Delivery Between Physicians and Nurse Practitioners: A Narrative Review
There is a growing demand for primary care physicians (PCPs) in the United States due to an increasing physician shortage and a growing burden of chronic disease. As such, nurse practitioners (NPs) have increasingly served as frontline clinicians alongside PCPs. This narrative review aims to describe the scopes, responsibilities, and outcomes of primary care practice between the two professions. A comprehensive review of the literature was performed to explore similarities and differences in the practice, quality of care, patient satisfaction, access to services, and professional challenges faced by both provider groups. Evidence suggests that PCPs and NPs provide complementary care to improve healthcare access. PCPs and NPs share similar responsibilities, including but not limited to examining patients, diagnosing diseases, managing acute and chronic illnesses, developing treatment plans, and coordinating care. PCPs undergo more extensive training, manage complex and invasive procedures, and maintain higher confidence in performing such tasks. Clinical outcomes under NP care are generally comparable to physician care across common or mild primary care conditions. PCPs often have more successful outcomes with severe or complex diseases, managing severe psychiatric conditions, and delivering advanced procedures or therapies. However, higher patient satisfaction is reported with management by NPs. Evidence on prescribing patterns, particularly opioids, is mixed across regulatory environments. This review highlights the need for integrated care models and policy frameworks that optimize collaboration between physicians and NPs, ultimately strengthening the primary care workforce and improving population health outcomes.
- Open Access
- 14 December 2025
- Published by Elsevier in European Journal of Radiology
- Vol. 195, 112612
Diagnostic Performance of AI-Assisted Coronary CT Angiography: A Systematic Review and Meta-Analysis
- 14 December 2025
- Published by Elsevier in European Journal of Radiology
- Vol. 195, 112612
Open AccessDiagnostic Performance of AI-Assisted Coronary CT Angiography: A Systematic Review and Meta-Analysis
- Open Access
- 28 November 2025
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 52 (2) , 111318
Minimally invasive approaches for early-stage rectal cancer: A comparative analysis from the TriNetX network
- 28 November 2025
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 52 (2) , 111318
Open AccessMinimally invasive approaches for early-stage rectal cancer: A comparative analysis from the TriNetX network
- 9 October 2025
- Published by SAGE Publications in American Journal of Rhinology & Allergy
- Vol. 40 (1) , 72-80
Divergent Risk Patterns of Upper Airway Inflammation in Autoimmune Diseases: A Nationwide Retrospective Analysis
Objectives: While autoimmune diseases (ADs) are known for systemic inflammation, their specific association with upper airway inflammation (UAI) has not been extensively characterized. We aim to investigate the associations between various ADs and subsequent UAI development in a large, national cohort. Methods: This retrospective cohort study utilized de-identified electronic health records from TriNetX, a national collaborative database. Adolescent and adult patients with a diagnosis of 1 or more ADs were identified. A 12 month washout period was implemented to exclude preexisting UAI. The primary outcome was the incidence of UAI (chronic rhinosinusitis, allergic rhinitis, nonallergic rhinitis, chronic laryngitis, obstructive sleep apnea) following AD diagnosis. Hazard ratios and relative risks (RRs) with 95% confidence intervals (CIs) were calculated. Results: After propensity matching, 1 327 186 patients with ADs and 1 327 186 controls were included. Patients with ADs exhibited a significantly lower overall incidence of UAI compared to controls (9.11% vs 13.81%; RR 0.71, 95% CI 0.70-0.71). This reduced risk was notable for allergic rhinitis (RR 0.64, 95% CI 0.64-0.65) and chronic sinusitis (RR 0.88, 95% CI 0.87-0.89). Juvenile idiopathic arthritis and type 1 diabetes demonstrated the most pronounced reductions in UAI risk. However, granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis were associated with a significantly increased risk of UAI. Conclusion: Most ADs were associated with a reduced overall risk of subsequent UAI. However, certain vasculitides significantly increased UAI risk, highlighting disease-specific pathophysiological mechanisms. These findings suggest a complex interplay between systemic autoimmunity and localized airway inflammation, warranting further investigation into underlying mechanisms and the impact of AD treatments.
- 9 October 2025
- Published by SAGE Publications in American Journal of Rhinology & Allergy
- Vol. 40 (1) , 72-80
Divergent Risk Patterns of Upper Airway Inflammation in Autoimmune Diseases: A Nationwide Retrospective Analysis
Objectives: While autoimmune diseases (ADs) are known for systemic inflammation, their specific association with upper airway inflammation (UAI) has not been extensively characterized. We aim to investigate the associations between various ADs and subsequent UAI development in a large, national cohort. Methods: This retrospective cohort study utilized de-identified electronic health records from TriNetX, a national collaborative database. Adolescent and adult patients with a diagnosis of 1 or more ADs were identified. A 12 month washout period was implemented to exclude preexisting UAI. The primary outcome was the incidence of UAI (chronic rhinosinusitis, allergic rhinitis, nonallergic rhinitis, chronic laryngitis, obstructive sleep apnea) following AD diagnosis. Hazard ratios and relative risks (RRs) with 95% confidence intervals (CIs) were calculated. Results: After propensity matching, 1 327 186 patients with ADs and 1 327 186 controls were included. Patients with ADs exhibited a significantly lower overall incidence of UAI compared to controls (9.11% vs 13.81%; RR 0.71, 95% CI 0.70-0.71). This reduced risk was notable for allergic rhinitis (RR 0.64, 95% CI 0.64-0.65) and chronic sinusitis (RR 0.88, 95% CI 0.87-0.89). Juvenile idiopathic arthritis and type 1 diabetes demonstrated the most pronounced reductions in UAI risk. However, granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis were associated with a significantly increased risk of UAI. Conclusion: Most ADs were associated with a reduced overall risk of subsequent UAI. However, certain vasculitides significantly increased UAI risk, highlighting disease-specific pathophysiological mechanisms. These findings suggest a complex interplay between systemic autoimmunity and localized airway inflammation, warranting further investigation into underlying mechanisms and the impact of AD treatments.
- Open Access
Survival Benefits of GLP-1 Receptor Agonists in Patients with Neuroendocrine Neoplasms: A Large-Scale Propensity-Matched Cohort Study
Background: Neuroendocrine neoplasms (NENs) represent a heterogeneous group of malignancies that consist of two major subtypes: neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs). Glucagon-like peptide-1 receptor agonists (GLP-1Ra) have demonstrated favorable results in preclinical studies, but their impact on NEN outcomes remains unexplored. Methods: Using the TriNetX US Research Network, we identified adult patients with NEN and either diabetes or obesity. After 1:1 propensity score matching based on demographics, comorbidities, procedures, and medication use, we compared survival outcomes between patients who received GLP-1Ra after NEN diagnosis and those who did not. Results: Among 32,464 eligible patients, 3139 received GLP-1Ra and 29,325 did not. After propensity matching, each cohort included 3043 patients with well-balanced baseline characteristics. During follow-up periods extending up to 15 years, all-cause mortality occurred in 356 (11.7%) GLP-1Ra users versus 753 (24.7%) non-users, representing a 13.0% absolute risk reduction (p < 0.001). GLP-1Ra use was associated with significantly improved survival (HR = 0.56, 95%CI = 0.49–0.63, p < 0.001). Both well-differentiated (HR = 0.52) and poorly differentiated tumors (HR = 0.56) showed significant improvement. Among primary sites, lung NENs demonstrated the most pronounced benefit (HR = 0.42). Tirzepatide showed the strongest association with reduced mortality (HR = 0.16), followed by semaglutide (HR = 0.27) and dulaglutide (HR = 0.52). Results: In this large propensity-matched study, GLP-1Ra use was associated with a 44.3% reduction in mortality risk among NEN patients with diabetes or obesity. The magnitude of the observed benefit suggests a potential role for GLP-1Ra as adjunctive therapy in this patient population. Prospective clinical trials are warranted to confirm these findings and explore underlying mechanisms.
Open AccessSurvival Benefits of GLP-1 Receptor Agonists in Patients with Neuroendocrine Neoplasms: A Large-Scale Propensity-Matched Cohort Study
Background: Neuroendocrine neoplasms (NENs) represent a heterogeneous group of malignancies that consist of two major subtypes: neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs). Glucagon-like peptide-1 receptor agonists (GLP-1Ra) have demonstrated favorable results in preclinical studies, but their impact on NEN outcomes remains unexplored. Methods: Using the TriNetX US Research Network, we identified adult patients with NEN and either diabetes or obesity. After 1:1 propensity score matching based on demographics, comorbidities, procedures, and medication use, we compared survival outcomes between patients who received GLP-1Ra after NEN diagnosis and those who did not. Results: Among 32,464 eligible patients, 3139 received GLP-1Ra and 29,325 did not. After propensity matching, each cohort included 3043 patients with well-balanced baseline characteristics. During follow-up periods extending up to 15 years, all-cause mortality occurred in 356 (11.7%) GLP-1Ra users versus 753 (24.7%) non-users, representing a 13.0% absolute risk reduction (p < 0.001). GLP-1Ra use was associated with significantly improved survival (HR = 0.56, 95%CI = 0.49–0.63, p < 0.001). Both well-differentiated (HR = 0.52) and poorly differentiated tumors (HR = 0.56) showed significant improvement. Among primary sites, lung NENs demonstrated the most pronounced benefit (HR = 0.42). Tirzepatide showed the strongest association with reduced mortality (HR = 0.16), followed by semaglutide (HR = 0.27) and dulaglutide (HR = 0.52). Results: In this large propensity-matched study, GLP-1Ra use was associated with a 44.3% reduction in mortality risk among NEN patients with diabetes or obesity. The magnitude of the observed benefit suggests a potential role for GLP-1Ra as adjunctive therapy in this patient population. Prospective clinical trials are warranted to confirm these findings and explore underlying mechanisms.